Turowski G, Urban A, Cybulski L, Turaszwili T, Zubel M
Pol Med Sci Hist Bull (1973). 1976 Jan-Mar;15(1):51-8.
TFX (Thymus Factor X) extract from calf thymuses, was given for the first time in Poland to the patient suffering from advanced rectal cancer with perforation to the peritoneal cavity, diffuse fecal peritonitis and multiple metastases to the liver. The immunological, clinical and histopathological observations of the patient for the period of 12 months of treatment are presented. The patient was given the biologically active thymus extract in the total amount of 14.2 mg in 34 subcutaneous injections initially in single dose of 0.1 mg and later on in amount of 0.5 mg. The remarkable restoration of the immunological reactivity of the patient from a total energy to the state of hyperreactivity has to be emphasized. It has been confirmed by the delayed hypersensitivity skin tests (Rt-23, PHA), the increase of the number of RFC (TEa and TEt rosette test with the SRBC), the diminishing of the autolymphocytotoxicity of the peripheral lymphocytes (evaluated by DTL) and also by the high level of the absolute number of circulating lymphocytes in the peripheral blood. The improvement of the clinical condition of the patient consisted in total regression of the inflammatory and functional changes in the respiratory and cardiovascular systems and also in the renal function. The regular rectal endoscopic examinations of the patient revealed the diminished size of the tumor and its unusual appearance described as an induration and sharp delimitation from the surrounding tissues. The histological examinations performed 5 times during the observation period of 11 months revaled the essential changes in the structure of the growth: the marked increase of the stroma with the signs of active proliferation, foci calcification and ossification. These changes were interpreted as extremely rare in the rectal cancer stroma and are considered to represent dystrophic calcification at the neoplastic foci followed by ossification. It should be also pointed out that twelve months survival of the patient with advanced rectal cancer and multiple metastases to the liver represents an unusually long rate in comparison to that generally accepted in the literature for this grade of rectal cancer advancement.
从牛胸腺中提取的TFX(胸腺因子X)首次在波兰给予一名患有晚期直肠癌且已穿孔至腹腔、弥漫性粪性腹膜炎并伴有肝多发转移的患者。本文呈现了该患者在12个月治疗期间的免疫学、临床及组织病理学观察结果。患者最初单次皮下注射0.1毫克,共34次皮下注射,给予生物活性胸腺提取物总量达14.2毫克,之后每次注射量为0.5毫克。必须强调的是,患者的免疫反应性从完全无反应显著恢复至高反应状态。这已通过迟发型超敏皮肤试验(Rt - 23、PHA)、RFC数量增加(用SRBC进行TEa和TEt玫瑰花结试验)、外周淋巴细胞自身淋巴细胞毒性降低(通过DTL评估)以及外周血中循环淋巴细胞绝对数量的高水平得到证实。患者临床状况的改善表现为呼吸、心血管系统以及肾功能方面的炎症和功能变化完全消退。对患者定期进行直肠内镜检查发现肿瘤体积缩小,其外观异常,表现为硬结且与周围组织界限清晰。在11个月的观察期内进行了5次组织学检查,结果显示肿瘤结构发生了本质变化:基质显著增加,伴有活跃增殖迹象、灶性钙化和骨化。这些变化在直肠癌基质中极为罕见,被认为代表肿瘤灶处的营养不良性钙化,随后发生骨化。还应指出的是,与文献中普遍接受的该级直肠癌进展情况相比,该晚期直肠癌伴肝多发转移患者存活12个月的时间异常之长。